Article

CURE Magazine and Incyte to Honor MPN Heroes

Author(s):

Award reception and gala will recognize the work and achievements of individuals dedicated to improving the lives of people living with rare blood disorders

CURE™ magazine will host the 2nd Annual MPN Heroes recognition reception on December 5, 2014, in San Francisco prior to the American Society of Hematology’s annual meeting. The MPN Heroes event will honor clinicians, caregivers, and advocates who have made significant contributions in the field of myeloproliferative neoplasms (MPNs).

Special guest speaker Charles Esten, from the TV show "Nashville," will discuss his family's cancer journey at the reception. Over a decade ago, Esten's daughter was diagnosed with acute lymphoblastic leukemia and is now in remission. Following this experience, Esten has become a honorary spokesperson for cancer education and he and his family have joined the battle to fund the research that will help families who are faced with blood cancers.

“This event showcases everything our company and CURE magazine supports. It’s an honor for us to be able to recognize the achievements and accomplishments of these outstanding individuals,” said Mike Hennessy, Jr., President of Cure Media Group.

MPN Heroes is also supported by Incyte Corporation, CancerCare, Cancer Support Community, Leukemia & Lymphoma Society, MPN Education Foundation, MPN Research Foundation, and MPN Education Foundation, and National Organization for Rare Disorders.

To further increase awareness of MPNs, Incyte has announced it will make a charitable donation to an organization engaged in MPN activities on behalf of each Hero recognized for their impact on the broader MPN community.

“The men and women who will be recognized at this event continue to inspire us with their dedication and devotion to the MPN community,” said Hervé Hoppenot, President and Chief Executive Officer, Incyte.

“CURE has been the source of information and inspiration for many patients, caregivers, and families since 2002. The MPN Heroes event is one of many resources that CURE offers, and represents our commitment to enhancing cancer care and improving outcomes,” said Silas Inman, Director of Editorial and Multimedia for Cure Media Group.

Visit http://www.MPNHeroes.com to learn more about MPN Heroes and for a list of the steering committee members who selected the finalists for this year’s awards.

About CURE Media Group

About Incyte

Contacts:

Supporting the recognition of MPN Heroes and the MPN community is an ongoing effort of Incyte’s Voices of MPN™ awareness program. For every post made on The Wall of Voices, Incyte will donate five dollars to the MPN Research Foundation. For more information, visit http://www.voicesofmpn.com.CURE Media Group, through its unique and award-winning products, has been a source of information and inspiration for patients and families on the cancer journey since 2002. CURE Media Group’s flagship product, CURE magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers, and advocacy groups. Through the magazine, live meetings, a resource guide for the newly diagnosed, the Extraordinary Healers national nursing award, and other books and online tools, CURE Media Group combines science and humanity to make cancer understandable. CURE Media Group is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, which includes the acclaimed OncLive (https://www.onclive.com) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com or http://www.mjhassoc.com.Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology. For additional information on Incyte, please visit the Company's website at http://www.incyte.com.Cure Media Group

Silas Inman

Phone: (609) 716-7777, ext. 233

E-mail: sinman@onclive.com

Incyte Media Inquiries:

Mariesa Kemble

Sam Brown Inc.

Phone: (608) 850-4745

E-mail: mariesakemble@sambrown.com

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.